Pfizer
Pfizer launches new website for Dupuytren’s disease
June 12, 2012Medical Communications, Sales and Marketing Dupuytren's disease, Pfizer, Xiapex, it is in your hands
Pfizer has released a new interactive video and website aimed at helping people with Dupuytren’s disease, a debilitating hand condition. …
Pfizer to create standalone animal health business
June 8, 2012Sales and Marketing Ian Read, Pfizer, Zoetis, nestle, standalone
Pfizer has said it is setting up a new standalone company out of its animal health division. This means it …
Lipitor fallout prompts Pfizer to cut Irish workforce
June 7, 2012Manufacturing and Production Amgen, Ireland, Lipitor, Pfizer, cuts, patent loss
Falling demand for blockbuster cholesterol drug Lipitor has prompted Pfizer to cut staff levels at two manufacturing facilities in Ireland. …
Pfizer appoints two senior roles
May 24, 2012Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Pfizer, Read
Pfizer has named Olivier Brandicourt as president and general manager of its Emerging Markets and Established Products Business Units, and …
Plavix loses US patent protection
May 18, 2012Sales and Marketing BMS, FDA, Lipitor, Pfizer, Plavix, Sanofi
Sanofi and Bristol-Myers Squibb’s blood thinner Plavix has lost its patent protection in the US. The drug, which made $6.6 …
NICE comes out fighting against appraisal delays story
May 17, 2012Sales and Marketing Daily Mail, Dillon, NHS, NICE, Pfizer, Victrelis
NICE has criticised a report that says the watchdog has taken up to nine years to appraise certain drugs. The …
Torisel fails in head-to-head study with Nexavar
May 16, 2012Research and Development, Sales and Marketing Bayer, Nexavar, Pfizer, Torisel, inlyta, rcc
Pfizer’s kidney cancer drug Torisel has failed to best Bayer’s Nexavar in a head-to-head trial. The Phase III study was …
Pfizer’s RA drug on course for approval
May 10, 2012Sales and Marketing Humira, JAK inhibitor, Pfizer, RA, rheumatoid arthritis, tofacitinib
An FDA advisory committee has recommended for approval Pfizer’s new rheumatoid arthritis treatment tofacitinib.The Arthritis Advisory Committee voted 8-2 to …
Novo Nordisk appoints ex-Pfizer head
May 10, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Novo Nordisk, Pfizer, Robert Clark, regulatory affairs
Robert Clark will be joining Novo Nordisk as vice president, regulatory affairs. Clark will lead Novo Nordisk’s US regulatory team, …
Lyrica fails in diabetes and HIV pain
May 9, 2012Sales and Marketing Lyrica, Pfizer, neuropathic pain, pain
Two separate Phase III trials of Lyrica have failed to show benefits in treating nerve pain – one in HIV …
Pfizer releases new data for Pristiq
May 9, 2012Research and Development, Sales and Marketing Effexor, MDD, Pfizer, Pristiq, antidepressant
Pfizer has released positive data for its established antidepressant Pristiq, as it hopes to extend the use of the drug. …
Teva launches first generic Lipitor in UK
May 8, 2012Sales and Marketing Lipitor, NHS, Pfizer, Teva, atorvastatin
Teva has launched the first generic Lipitor in the UK on the day the drug loses its patent protection. The …
Roche and Novartis have best websites
May 3, 2012Medical Communications Bowen Craggs & Co, Novartis, Pfizer, Roche, Shell, digital, web
A new survey of leading international companies has found Roche and Novartis have the best websites in the pharma sector. …
Pfizer enters Gaucher disease market
May 3, 2012Sales and Marketing Cerezyme, Elelyso, Gaucher, Genzyme, Pfizer, Shire, Vpriv
Pfizer has gained FDA approval for its new Gaucher disease drug Elelyso. Elelyso (taliglucerase alfa) is an enzyme replacement therapy …
Lipitor losses hit Pfizer
May 2, 2012Sales and Marketing Alzheimer's, Lipitor, Pfizer, patent expiry
Lipitor’s US patent expiry has inflicted heavy damage on Pfizer’s revenues, with global sales down 7% in the first three …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
